Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Callaghan

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology and Therapeutics|May 1, 1980
Pergolide, a potent long-acting dopamine-receptor agonistL Lemberger, R Crabtree, J T Callaghan
Archives of Neurology|June 1, 1981
CSF perfusion to treat intraventricular penicillin toxicityJ T Callaghan, J I Ausman, R Clubb
Drugs|January 1, 1988
Double-blind comparator trials with pinacidil, a potassium channel openerJ T Callaghan, M R Goldberg, R Brunelle
Biomaterials|June 7, 2005
The physical properties and response of osteoblasts to solution cast films of PLGA doped polycaprolactoneZ G Tang, J T Callaghan, J A Hunt
Clinical Immunology and Immunopathology|April 1, 1983
Suppression of mitogen-induced lymphocyte transformation in cigarette smokersB H Petersen, L F Steimel, J T Callaghan
Life Sciences|January 5, 1981
Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivativeJ T Callaghan, R E Cleary, R Crabtree, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1986
Nizatidine, an H2-blocker. Its metabolism and disposition in manM P Knadler, R F Bergstrom, J T Callaghan, et al.
Journal of Clinical Pharmacology|August 1, 1987
Nizatidine, and H2-receptor antagonist: disposition and safety in the elderlyJ T Callaghan, A Rubin, M P Knadler, et al.
European Journal of Clinical Pharmacology|January 1, 1983
Effect of cholestyramine and colestipol on the absorption of phenytoinJ T Callaghan, M Tsuru, J L Holtzman, et al.
Clinical Pharmacokinetics|October 8, 1999
Olanzapine. Pharmacokinetic and pharmacodynamic profileJ T Callaghan, R F Bergstrom, L R Ptak, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology and Therapeutics|May 1, 1980
Pergolide, a potent long-acting dopamine-receptor agonistL Lemberger, R Crabtree, J T Callaghan
Archives of Neurology|June 1, 1981
CSF perfusion to treat intraventricular penicillin toxicityJ T Callaghan, J I Ausman, R Clubb
Drugs|January 1, 1988
Double-blind comparator trials with pinacidil, a potassium channel openerJ T Callaghan, M R Goldberg, R Brunelle
Biomaterials|June 7, 2005
The physical properties and response of osteoblasts to solution cast films of PLGA doped polycaprolactoneZ G Tang, J T Callaghan, J A Hunt
Clinical Immunology and Immunopathology|April 1, 1983
Suppression of mitogen-induced lymphocyte transformation in cigarette smokersB H Petersen, L F Steimel, J T Callaghan
Life Sciences|January 5, 1981
Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivativeJ T Callaghan, R E Cleary, R Crabtree, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1986
Nizatidine, an H2-blocker. Its metabolism and disposition in manM P Knadler, R F Bergstrom, J T Callaghan, et al.
Journal of Clinical Pharmacology|August 1, 1987
Nizatidine, and H2-receptor antagonist: disposition and safety in the elderlyJ T Callaghan, A Rubin, M P Knadler, et al.
European Journal of Clinical Pharmacology|January 1, 1983
Effect of cholestyramine and colestipol on the absorption of phenytoinJ T Callaghan, M Tsuru, J L Holtzman, et al.
Clinical Pharmacokinetics|October 8, 1999
Olanzapine. Pharmacokinetic and pharmacodynamic profileJ T Callaghan, R F Bergstrom, L R Ptak, et al.
Pageof 4